Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
D.M. Graham Laboratories
Hobart, New York, USA
- Ownership
- Private
- Development stage
- Other
01
Overview
D.M. Graham Laboratories was a pharmaceutical company specializing in the development and manufacture of generic drugs, with a particular focus on controlled substances and analgesics. Based in Hobart, New York, the company operated as a contract manufacturer and a developer of its own generic product line. In 1998, it was acquired by Mallinckrodt for approximately 52 million dollars to strengthen Mallinckrodt's position in the pain management and generic pharmaceutical markets. The facility in Hobart continued to serve as a significant manufacturing site for Mallinckrodt following the acquisition, focusing on the production of dosage-form generic narcotics.
- Therapeutic areas
- Neurology
- Modalities
- Small molecule
- Industry
- Biotech
Beyond the preview
Go deeper on D.M. Graham Laboratories.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on D.M. Graham Laboratories.